Keytruda

White House unveils plans to reimport medicines from Canada

Keytruda, to name but two.

Keytruda scores in neoadjuvant triple negative breast cancer combo

Interim analysis by the independent Data Monitoring Committee (DMC) showed that Keytruda demonstrated a statistically significant improvement in pathological complete response (pCR) rates when compared to chemotherapy alone. ... In this trial, Keytruda

CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

The approval, based on the results of the IMpower130 trial, could help Roche try to build in first-line NSCLC, an indication dominated by Merck &Co’s Keytruda (pembrolizumab). ... Merck picked up another positive opinion for Keytruda, this time for use

Opdivo trial overshadows BMS financial results

That is a surprising outcome given that Keytruda plus chemo was a clear winner over chemo alone in phase 3 testing, a result that has driven its use in the ... The jury is however out on whether patients and payers will plump for that option over

New products help lift Roche outlook despite biosimilar onslaught

$787m). Roche now expects to shortly unveil phase 3 results in liver cancer, which will help Tecentriq consolidate its position as the third biggest checkpoint inhibitor behind Merck &Co's Keytruda

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]